Zai Lab Limited (ZLAB)
NEUTRALFondamentale
45
Prezzo
$26.36
Capitalizzazione
$2.84B
Parte 1 · Quanto vale l'azienda
Panoramica
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Per questa società non c'è ancora una scheda redazionale
Per questa società non c'è ancora un elenco di concorrenti.
Stato Patrimoniale e Liquidità
Ricavi
$444M
Ultimi 12 mesi (al 30/06/2026)
Utile Netto
$-188M
Ultimi 12 mesi (al 30/06/2026)
Free Cash Flow
$-159M
Patrimonio Netto Totale
$716M
Passività Totali
$457M
Rapporto di Liquidità
2.13
Copertura Interessi
44.13
Debito/EBITDA
-
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$32.39
Prezzo Attuale
$26.36
Margine di Sicurezza
+18.6%
Range Fair Value
$30.77 - $34.01
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
-
ROE
-24.5%
Rapporto P/B
47.41
P/FCF
-
Margine Lordo
55.9%
ROIC
-32.3%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
-32.3%
WACC
7.9%
ROIC − WACC
-40.2 pp
Il ROIC è sotto il costo del capitale: l'azienda distrugge valore per ogni dollaro investito.
Criteri di Analisi Fondamentale
Superati (10)
- EPS shows upward trend
- Gross Margin 55.9%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 56.5%
- Analyst Consensus 79% Buy
- Earnings Surprise avg 19.0%
- Net Margin Trend -42.4% vs -50.0%
Non superati (10)
- Price CAGR 2.28%
- ROIC -32.3%
- P/B Ratio 47.41
- Operating Margin -59.5%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -27.4%
- Share Dilution 10.9%
- Piotroski F-Score 3/9
Non disponibili (7)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preoccupazioni finanziarie serie
Qualità degli Utili
Bassa qualità: indagare la contabilità
Diluizione Azionaria
Emissione nuove azioni, diluizione proprietà
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 59 |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research & Development | 61 |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer | 57 |
| Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Corporate Secretary | 59 |
| Ms. Christine Chiou | Senior VP & Head of Investor Relations | - |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Global R&D | 61 |
| Dr. Shan He Ph.D. | Senior VP & Chief Business Officer | - |
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Ultime Notizie
Ultime notizie per ZLAB, da Markets Gazette.
- 2/26/2026NEUTRALZai Lab Q4 Earnings Summary & Key Takeaways
Zai Lab has released a summary of its fourth-quarter earnings, a crucial event for investors tracking the biopharmaceutical company's performance. While specific details regarding revenues, earnings per share, and future outlook were not disclosed in this preliminary note, market attention is now focused on the in-depth analysis of these figures. Investors will be keen to understand how Zai Lab's key drugs, such as Zejula and Optune, contributed to growth and what the forecasts are for 2026, especially concerning clinical developments and regulatory approvals. The significance of these 'key takeaways' lies in their potential to influence expectations and the stock's valuation in the short to medium term.
via Markets Gazette